Heart Failure Treatment from Berlin Cures Shows Promise in Phase I Study.

Zug, Switzerland, and Berlin, Feb. 26, 2018

The first drug designed to eliminate autoantibodies that are a major cause of heart failure and to treat heart failure symptoms was effective and well-tolerated in a Phase I clinical study, according to an oral presentation that the drug’s developer, Berlin Cures, will make on March 11 at the American College of Cardiology’s 2018 annual scientific session in Orlando, Florida.

The DNA aptamer-based compound, known as BC 007, bound to and eliminated pathogenic autoantibodies directed against the beta-1 adrenoceptor, a receptor that regulates the heart’s rate and contraction strength. Heart cells are harmed by autoantibodies that chronically bind to this receptor in a process that has been found to lead to heart cell death and organ failure in 80 percent of dilated cardiomyopathy patients.

In dilated cardiomyopathy, the heart’s main pumping chamber, the left ventricle, is enlarged and weakened, decreasing the heart’s ability to sufficiently pump blood. There are approximately five million people with dilated cardiomyopathy in the United States and Europe.In the United States alone, dilated cardiomyopathy causes approximately 10,000 deaths and 46,000 hospitalizations each year and is the most common reason for heart transplantation and the implantation of expensive cardiac assist devices.

Clinical researchers evaluated 68 subjects in the Phase I study and determined that a single dose of intravenous infusion of BC 007 is able to eliminate autoantibodies targeting the beta-1 adrenoceptor completely and sustainably.BC 007 was extremely well tolerated and did not provoke any clinically relevant side effects.

With BC 007, we’ve demonstrated the effectiveness of treating heart failure.

In an earlier study of 163 patients taking full anti-heart failure medication as they awaited heart transplantation, autoantibodies targeting the beta-1 adrenoceptor were eliminated by a complex blood washing procedure known as immunoadsorption, leading to significantly improved heart function and to a pronounced increase in the probability of survival. Five years after first undergoing immunoadsorption, patients had a 43 percent greater probability of survival than patients who did not undergo immunoadsorption. The findings were first reported in the August 2012 edition of the European Journal of Heart Failure.

In addition to eliminating autoantibodies targeting the beta-1 adrenoceptor, BC 007 neutralized other autoantibodies belonging to the same large family of cell-surface receptors known as G protein-coupled receptors.

In fact, because BC 007 has shown a high affinity and specificity for all G protein-coupled receptor autoantibodies, Berlin Cures is developing additional aptamer drugs based on BC 007’s mechanism of action to eliminate other GPCR autoantibodies linked to pulmonary hypertension, glaucoma, pre-eclampsia and other diseases.

“With BC 007, we’ve demonstrated the effectiveness of treating heart failure that’s triggered by the pathogenic functional autoantibodies present in the vast majority of patients with dilated cardiomyopathy,” Berlin Cures founder, chairman and president Dr. Johannes Müller said.

Berlin Cures plans to begin Phase II clinical testing of BC 007 in the second quarter of 2018.

Please use a modern web browser